PDS Biotechnology Corp (PDSB) Stock Analysis

PDS Biotechnology Corp (PDSB) is a publicly traded company in the HEALTHCARE sector. It trades at $1.14, carries a market capitalization of $63.63M. This page summarizes the public market data, fundamentals, and frequently asked questions for PDSB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.14
• Market Cap: $63.63M
• EPS: $-0.66
• 52-Week High: $1.92
• 52-Week Low: $0.51

Market Sentiment

PDS Biotechnology Corp currently has a Neutral sentiment score of 0.08.

About PDS Biotechnology Corp

PDS Biotechnology Corporation (PDSB), headquartered in Florham Park, New Jersey, is a clinical-stage biopharmaceutical company pioneering innovative cancer immunotherapies through its proprietary Versamune® platform. The company is focused on developing multifunctional therapies that significantly enhance the immune response against cancer, with its lead candidate, PDS0101, undergoing clinical trials for HPV-related cancers. PDSB's commitment to efficacy and safety addresses critical unmet me...

GNG Research Analysis

GNG Research scores PDS Biotechnology Corp (PDSB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PDSB.

Frequently Asked Questions

Does PDSB pay dividends?

PDS Biotechnology Corp (PDSB) does not currently pay a regular dividend.

What is PDSB's market cap?

PDS Biotechnology Corp (PDSB) has a market capitalization of $63.63M with a current stock price of $1.14.